Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug896 | Chest MRI Wiki | 0.71 |
| drug4545 | labs Wiki | 0.71 |
| drug2998 | Placebos Wiki | 0.17 |
Navigate: Correlations HPO
There are 2 clinical trials
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Description: Number of subjects that must be hospitalized for COVID-19 during the conduct of this study
Measure: Incidence of hospitalization for COVID-19 Time: week 0 through week 26 (end of study)Description: Number of subjects who experience symptoms defined to be associated with COVID-19, such as fever, shortness of breath/difficulty breathing, cough.
Measure: Incidence of symptoms associated with COVID-19 Time: week 0 through week 26 (end of study)Description: Number of subjects that develop upper/lower respiratory infection with hospitalization criteria
Measure: Absence of upper/lower respiratory infection Time: week 0 through week 26Description: change from baseline in leukocyte differential
Measure: Leukocyte differential Time: weeks 0, 6, 14, 26Description: change from baseline in C Reactive protein
Measure: C Reactive protein Time: weeks 0, 6, 14, 26Description: change from baseline in TNF alpha
Measure: TNF alpha Time: weeks 0, 6, 14, 26Description: change from baseline in IL-6
Measure: IL-6 Time: weeks 0, 6, 14, 26Description: change from baseline in IL-10
Measure: IL-10 Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of glucose in the blood (mg/dL)
Measure: Glucose Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of calcium in the blood (mg/dL)
Measure: Calcium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of albumin in the blood (g/dL)
Measure: Albumin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total protein in the blood (g/dL)
Measure: Total protein Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of sodium in the blood (mol/L)
Measure: Sodium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total carbon dioxide in the blood (mmol/L)
Measure: Total carbon dioxide Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of potassium in the blood (mmol/L)
Measure: Potassium Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of chloride in the blood (mmol/L)
Measure: Chloride Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of BUN in the blood (mg/dL)
Measure: BUN Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of creatinine in the blood (mg/dL)
Measure: Creatinine Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
Measure: Alkaline phosphatase Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
Measure: Alanine aminotransferase Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total bilirubin in the blood (mg/dL)
Measure: Total bilirubin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)
Measure: white blood cells Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)
Measure: red blood cells Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hemoglobin in the blood (g/dL)
Measure: hemoglobin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hematocrit in the blood (%)
Measure: hematocrit Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular volume in the blood (fL)
Measure: mean corpuscular volume Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)
Measure: mean corpuscular hemoglobin Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin concentration in the blood (g/dL)
Measure: mean corpuscular hemoglobin concentration Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of red cell distribution width in the blood (%)
Measure: red cell distribution width Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of neutrophils in the blood (%)
Measure: neutrophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of lymphocytes in the blood (%)
Measure: Lymphs Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of monocytes in the blood (%)
Measure: Monocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of eosinophils in the blood (%)
Measure: Eosinophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of basophils in the blood (%)
Measure: Basophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)
Measure: Absolute neutrophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute lymphocytes in the blood (x 10^3/uL)
Measure: Absolute lymphs Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)
Measure: Absolute monocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)
Measure: Absolute eosinophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)
Measure: Absolute basophils Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of immature granulocytes in the blood (x 10^3/uL)
Measure: Immature granulocytes Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of platelets in the blood (x 10^3/uL)
Measure: Platelets Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of time for blood to coagulate (seconds)
Measure: Prothrombin time Time: weeks 0, 6, 14, 26Description: clinical lab evaluation of international normalized ratio of blood coagulation (no unit)
Measure: INR Time: weeks 0, 6, 14, 26Description: Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability
Measure: SF-36 Time: weeks 0, 6, 14, 26Description: Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression
Measure: PHQ-9 Time: weeks 0, 6, 14, 26Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Description: Number of subjects that require hospitalization for COVID-19
Measure: Incidence of hospitalization for COVID-19 Time: Week 0 through week 26 (end of study)Description: Number of subjects that develop symptoms associated with COVID-19, such as fever, shortness of breath/difficulty breathing, cough
Measure: Incidence of symptoms for COVID-19 Time: week 0 through week 26 (end of study)Description: absence of upper/lower respiratory infection by hospitalization criteria
Measure: absence of upper/lower respiratory infection Time: Weeks 0 through 26Description: clinical lab evaluation of level of glucose in the blood (mg/dL)
Measure: Glucose Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of calcium in the blood (mg/dL)
Measure: Calcium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of albumin in the blood (g/dL)
Measure: Albumin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total protein in the blood (g/dL)
Measure: Total Protein Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of sodium in the blood (mol/L)
Measure: Sodium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of carbon dioxide in the blood (mmol/L)
Measure: Total carbon dioxide Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of potassium in the blood (mmol/L)
Measure: Potassium Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of chloride in the blood (mmol/L)
Measure: Chloride Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of BUN in the blood (mg/dL)
Measure: BUN Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of creatinine in the blood (mg/dL)
Measure: Creatinine Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
Measure: Alkaline phosphatase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
Measure: Alanine aminotransferase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of aspartate aminotransferase in the blood (IU/L)
Measure: Aspartate aminotransferase Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of total bilirubin in the blood (mg/dL)
Measure: Total bilirubin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)
Measure: White blood cells Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)
Measure: Red blood cells Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hemoglobin in the blood (g/dL)
Measure: Hemoglobin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of level of hematocrit in the blood (%)
Measure: Hematocrit Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular volume in the blood (fL)
Measure: Mean corpuscular volume Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)
Measure: Mean corpuscular hemoglobin Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of mean corpuscular hemoglobin in the blood (g/dL)
Measure: Mean corpuscular hemoglobin concentration Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of red blood cell distribution width in the blood (%)
Measure: Red cell distribution width Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of neutrophils in the blood (%)
Measure: Neutrophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of lymphocytes in the blood (%)
Measure: Lymphs Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of monocytes in the blood (%)
Measure: Monocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of eosinophils in the blood (%)
Measure: Eos Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of basophils in the blood (%)
Measure: Basophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)
Measure: Absolute neutrophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute lymphs in the blood (x 10^3/uL)
Measure: Absolute lymphs Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)
Measure: Absolute monocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)
Measure: Absolute eosinophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)
Measure: Absolute basophils Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of granulocytes in the blood (%)
Measure: Immature granulocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of granulocytes in the blood (x 10^3/uL)
Measure: Absolute Immature granulocytes Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of platelets in the blood (x 10^3/uL)
Measure: Platelets Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of time for blood to coagulate (seconds)
Measure: Prothrombin time Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of international normalized ratio of blood coagulation (no unit)
Measure: INR Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of tumor necrosis factor alpha in the blood (pg/mL)
Measure: TNFalpha Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-6 in the blood (pg/mL)
Measure: Interleukin-6 Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-10 in the blood (pg/mL)
Measure: Interleukin-10 Time: Weeks 0, 6, 14, 26Description: clinical lab evaluation of interleukin-10 in the blood (mg/L)
Measure: C-reactive protein Time: Weeks 0, 6, 14, 26Description: Short-form 36 Health Survey; scored on a scale of 0-100; lower score equals more disability.
Measure: SF-36 Time: Weeks 0, 6, 14, 26Description: Depression module; scores DSM-IV criteria 0-3 to monitor severity of depression.
Measure: PHQ-9 Time: Weeks 0, 6, 14, 26Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports